MOC Credit Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Learning Objectives: On completion of this article, you should be able to (1) identify risk factors for migraine headaches, (2) recognize key processes in the pathophysiology of migraines, and (3) review recent advances in the treatment of migraines.
Disclosures: As a provider accredited by ACCME, Mayo Clinic College of Medicine (Mayo School of Continuous Professional Development) must ensure balance, independence, objectivity, and scientific rigor in its educational activities. Course Director(s), Planning Committee members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of this information will be published in course materials so that those participants in the activity may formulate their own judgments regarding the presentation. In their editorial and administrative roles, Karl A. Nath, MB ChB, Terry L. Jopke, Kimberly D. Sankey, and Jenna M. Pederson, have control of the content of this program but have no relevant financial relationship(s) with industry. The authors report no competing interests. Method of Participation: In order to claim credit, participants must complete the following: 1. Read the activity. 2. Complete the online CME Test and Evaluation. Participants must achieve a score of 80% on the CME Test. One retake is allowed. Visit www.mayoclinicproceedings.org, select CME, and then select CME articles to locate this article online to access the online process. On successful completion of the online test and evaluation, you can instantly download and print your certificate of credit. 
Abstract
Migraine is a common disabling condition that is frequently managed by primary care providers. In recent years, the growing array of migraine therapies has added complexity to patient care. This article serves as a succinct review of pertinent updates and future directions regarding migraine. Our understanding of pathophysiology has progressed along with new advances in biomarkers and genetics. These discoveries have led to a wealth of new options for treatment, many of which are specifically targeted against molecules implicated in migraine headache such as calcitonin geneerelated peptide. These treatments include several monoclonal antibodies, calcitonin-gene related peptide receptor antagonists, and 5-hydroxytryptamine 1F (5-HT1F) receptor agonists; new options such as these are important for the large population falling out of eligibility for triptans. Furthermore, various nonpharmacological options including noninvasive brain stimulation have joined the arsenal of therapies used for treating migraine. M igraine is a common debilitating condition that results in extremely high cost to health care systems as well as patients because of lost productive time. Most patients with migraine present directly to their primary care physician (PCP), and the majority never receive care from a headache medicine specialistdeven if the migraines remain poorly controlled. Over the past several years, there have been major developments in the field of migraine, and this article serves as a review for PCPs to highlight some of the recent discoveries in the rapidly changing realm of migraine diagnosis and management.
EPIDEMIOLOGICAL DISCOVERIES AND MIGRAINE
According to the Global Burden of Disease Study 2013, 1 migraine is 1 of only 8 chronic medical conditions that affect more than 10% of the population worldwide. Furthermore, migraine is ranked sixth overall in terms of years with lived disability. A recent meta-analysis involving 6 million participants reported an overall increase in the prevalence of migraine worldwide (particularly in Africa, Asia, and South America), 2 which correlates with rising average life expectancy in developing countries and growth of urban livingda risk factor for migraine. Furthermore, a 2017 meta-analysis of nearly 300,000 patients controlled for known associations of age and sex revealed that migraine was 27% more likely to occur in overweight individuals, a population that has greatly increased worldwide. 3 Although PCPs are aware of the high epidemiological burden of migraine, survey-based research reveals that most are unfamiliar with the American Academy of Neurology guidelines on preventive medications and the American Board of Internal Medicine Foundation's Choosing Wisely Campaign recommendations for limiting unnecessary diagnostic tests. 4 
UPDATES ON PATHOPHYSIOLOGY AND BIOMARKERS
A multitude of clinical and basic science studies have shed light on the pathophysiology of migraine in recent years by using advanced imaging and neurophysiological investigations. Migraine is not only a headache but a syndrome of various phases, each with its own distinct pathogenesis and unique treatment. Briefly, the migraine prodrome, or premonitory phase, can occur several hours to days before a headache and may be hypothalamically modulated on the basis of advanced positron emission tomography and functional magnetic resonance imaging studies, although other brainstem and limbic structures may play a causal role as well. 5 The aura phase is caused by a dynamic event of cortical spreading depressionda slow wave of neural depolarizationdthat involves changes in brain gial activity and alteration of cerebral blood flow. The headache itself is a brain-based disorder that involves activation of the trigeminovascular system with release of various neurotransmitters, leading to an inflammatory cascade involving the meninges, meningeal arteries and veins, and cortical substance. 6 The final phase, or postdrome, has been the least studied. There is a paucity of information on the pathophysiology of the final phase, which typically includes non-headache symptoms such as malaise, fatigue, or gastrointestinal symptoms. Calcitonin geneerelated peptide (CGRP) is one of the primary neurotransmitters released during the migraine attack; its direct blockade aborts and even prevents migraines. 7, 8 Activation of trigeminal neurons may lead to central sensitization, which produces symptoms of allodynia (painful response to a nonepainful stimulus), a hallmark of the disorder.
Consistent with other advances in migraine research has been the identification of biomarkers in migraineurs. Glutamate, CGRP, b-endorphin, and nerve growth factor (NGF) levels have all been found to be substantially increased or decreased in the cerebrospinal fluid and blood (except NGF, which has only been found to be elevated in cerebrospinal fluid). 9 Glutamate has been implicated in the pathogenesis of cortical spreading depression; NGF and b-endorphin are thought to affect analgesia pathways. However, the optimal use of biomarkers for diagnosis, prognosis, and treatment is still to be determined.
An increased incidence of cerebrovascular disease in the absence of overt atherosclerotic disease suggests that migraine has a causal role in vascular inflammation or is itself another manifestation of unidentified vascular inflammation. For instance, migraine has a strong association with cryptogenic transient ischemic attack and ischemic stroke, which was found to be highest in older patients without vascular risk factors in a populationbased study of 1800 patients. 10 Further research is needed to clarify the pathophysiological relationship between migraine and other vascular abnormalities.
Much progress has been made on the genetic basis of migraine, which has revealed monogenic and polygenic subtypes of migraine as well. 6, 11, 12 Hemiplegic migraine is a rare subtype of monogenic migraine with aura associated with motor weakness. It is strongly associated with 3 specific genes: CACNA1A, ATP1A2, and SCN1A (for expansion of gene symbols, use search tool at www.genenames. org), all of which make the brain more susceptible to cortical spreading depression. 12 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, which is the most common heritable cause of stroke, is another monogenic neurological disorder that is highly associated with migraine. In terms of polygenic genetic basis for migraine, 38 different single nucleotide allelic variants were found to be associated with migraine in a 2016 meta-analysis of genome-wide association studies.
11 Only 1 genetic locus was found on the X chromosome, which is interesting given the preponderance of women migraineurs after puberty and the existence of perimenstrual migraine. Future studies will continue to investigate whether certain migraines, based on genetic subtype, respond best to specific medications.
NEW DEVELOPMENTS IN ESTABLISHED MIGRAINE TREATMENTS
Although nonpharmacological approaches are easily overlooked, they remain an integral part of migraine treatment. Primary care providers should encourage active participation by the patient and use strategies to avoid migraine triggers while optimizing modifiable risk factors for transformation to chronic migraine (chronic migraine is considered if at least 8 migraines per month with at least 15 monthly headache days lasting for 3 months occur). Common triggers include missing meals, poor sleep, caffeine, and artificial sweeteners; modifiable risk factors include body mass index (calculated as the weight in kilograms divided by the height in meters squared), medication overuse, alcohol and caffeine overuse, untreated obstructive sleep apnea, and stress. A systematic review of prognostic indicators for chronic migraine found evidence that most risk factors associated with poor outcomes are potentially modifiable; these include poor sleep, stress, selfefficacy, and mood disorders. 13 Psychological treatment such as cognitive behavioral therapy and relaxation therapy, in conjunction with preventive medications, has also been found to be effective in reducing frequency and severity of migraines and improving headache outcome measures and headache severity ranging from 20% to 67%. 14 Preventive treatment is an essential component of migraine care, but unfortunately, a large proportion of patients do not receive it, leading to more headache days, higher morbidity, and higher societal cost. The addition of a preventive medication should be considered when headaches are frequent and bothersome (typically at least 2-4 disabling migraines per month); it requires discussion of benefits and risks with the patient and is often patient specific. Various medications have been used to reduce headache frequency, which can be intimidating for PCPs seeking to initiate treatment. The most recent guidelines for the prevention of episodic migraines by the American Headache Society/ American Academy of Neurology, the Canadian Headache Society, and the European Federation of Neurological Societies were published in 2012. 15 The medications with the highest level of evidence for migraine prevention were sodium valproate, butterbur, topiramate, propranolol, timolol, and metoprolol. Although the aforementioned guidelines included only studies published up to 2009, a recent metaanalysis of more than 200 randomized controlled trials (RCTs) confirmed most of the findings of previous systematic reviews. 16 Successful treatment of migraines may be paradoxically achieved by reducing medication use. In medication overuse, headache worsening of a previous headache syndrome occurs because of the overuse of abortive pain medications. Medication overuse headache is defined as a headache occurring at least 15 days per month in patients with preexisting headache disorders and with concurrent use of either simple analgesic agents such as ibuprofen or naproxen at least 15 days per month or other analgesic agents such as triptans or ergotamines 10 days per month for at least 3 months. 17 Although withdrawal and reduction of abortive medications is considered to be the treatment, there is no standard practice recommended at this time. 6 Unfortunately, most patients are unaware of the risks of excessive drug intake, so providers should be diligent in evaluating the frequency of analgesic use. 17, 18 With the rise of complementary and alternative medicine worldwide, an increasing number of supplements and vitamins have been touted as effective migraine treatments. Many of these treatments have shown benefit, leading to varying degrees of endorsement in migraine guidelines for butterbur, feverfew, coenzyme Q10, and others. 19 Butterbur, however, has since been associated with rare but severe hepatotoxicity. Clinicians should be aware of the possibility of future guideline changes regarding complementary treatments of migraine.
Botulinum toxin type A, a protein produced by Clostridium botulinum, has exhibited benefit and is approved by the Food and Drug Administration (FDA) for use in chronic migraine. The use of botulinum toxin has become a valuable tool in the treatment of refractory migraine, exhibiting superiority over placebo in reduction of monthly headache days. The drug was approved in 2010 and is administered according to a specific protocol of 31 intramuscular injections, which can be repeated every 3 months. 20 A recent study used insurance claims data to show that botulinim toxin treatment significantly reduced headache-related emergency department visits and hospitalizations as compared with other oral preventive medications. 21 Botulinim toxin is typically reserved for patients who have failed 3 preventive medications and are experiencing chronic migraine per aforementioned criteria.
Various nonpharmacological treatments for migraine have been developed in recent years. Noninvasive brain stimulation is a broad term that includes transcutaneous magnetic stimulation (TMS) and transcutaneous direct current stimulation (tDCS). These modalities, which have been studied as preventive and abortive treatments, have the advantage of being noninvasive, painless, and rapidly administered. There are currently 2 main commercially available tDCS devices that have been studied in migraine: Cefaly (supraorbital stimulation) and gammaCore (vagus nerve stimulation).
Both are devices developed in the last decade that use tDCS to deliver low-dose electrical current and have been approved by the FDA for use in migraine. Few data are available from randomized sham-controlled studies to evaluate the efficacy of tDCS devices; however, subgroup analysis from a recent meta-analysis of noninvasive brain stimulation found moderate quality evidence suggesting that tDCS reduced pain intensity, number of migraines, and "painkiller" intake. 22 The Cefaly device has been shown in RCTs to be of benefit for both abortive and preventive therapy and is FDA approved for the prevention of episodic migraine. The gammaCore device (a peripheral vagal nerve stimulator) has shown efficacy in RCTs as an acute treatment for episodic and chronic migraines. 23 Transcutaneous magnetic stimulation, which applies magnetic impulse to the cerebral cortex, has shown some benefit for use as an abortive treatment for migraine. The open-label, multicenter eNeura SpringTMS Post-Market Observational U.S. Study of Migraine (ESPOUSE) Study, published in January 2018, suggested that TMS is safe and effective in the prevention of migraine. 24 Transcutaneous magnetic stimulation has been FDA approved as well. The previously mentioned systematic review and meta-analysis revealed that noninvasive brain stimulation, including TMS and tDCS, had low to very low quality of evidence and no clear benefit over sham treatment in a review of studies up to January 2016; since then, open-label studies have been generally positive, so the true benefit of these therapies remains to be seen.
Although many patients with migraine can be successfully managed by their primary care providers, several reasons exist for referral to neurology. These include failure of 1 to 2 common preventive medications, chronic migraine (as defined previously), diagnostic uncertainty or atypical features such as coincident transient neurologic deficits, refractory medication overuse headache (ie, the patient is unable to consistently reduce abortive medication use), and medical comorbidities such as vascular risk factors that preclude use of common abortive drugs and complicate management. 18 Other valuable referrals may include consultation with psychiatrists or sleep medicine specialists for comorbid mood disorder or obstructive sleep apnea.
NEW DEVELOPMENTS IN MIGRAINE TREATMENT
Several "migraine-specific" drugs have recently been developed, including CGRP receptor antagonists (abortive use) and monoclonal antibodies targeting CGRP (prophylactic use). These medications represent an advancement in the current treatment of migraine to specific tailored therapy based on known pathophysiological mechanisms. Several oral CGRP receptor antagonists under development have shown promising efficacy in treating migraine with superiority to placebo and comparability to triptans, but many of the trials have been discontinued because of the concerns of hepatotoxicity after taking the drug for multiple consecutive days. A phase II RCT published in 2016 found that ubrogepant, a CGRP receptor antagonist, yielded modest results as an abortive agent in single migraine pain freedom at 2 hours after medication administration as compared with placebo; there were no signs of hepatotoxicity within 1 week of drug administration. 25 In recent years, 4 monoclonal antibodies targeting CGRP or the CGRP receptor have been tested in humans for the prevention of migraine: galcanezumab, eptinezumab, erenumab, and fremanezumab. 6 High-quality RCTs have confirmed the efficacy of these antibodies in reducing migraine days in episodic migraine as well as chronic migraine. Fremanezumab exhibited efficacy in reducing monthly migraine days in a phase III trial of 1130 patients with chronic migraine. 8 Erenumab, the only monoclonal antibody that targets the CGRP receptor, exhibited similar efficacy for episodic migraine in addition to chronic migraine. 7 Reported reduction in monthly migraine days has been approximately 3 to 6 episodes per month and significantly greater than that with placebo. Of note, patients with chronic migraine were excluded from the previously cited studies if they had failed preventive treatment with 2 to 3 prophylactic medications. Despite the promising results of these positive trials, additional studies are needed to determine the long-term efficacy, safety, and cost-effectiveness of monoclonal antibodies. An analysis of a 5-year study of erenumab revealed sustained treatment effect and safety at week 64, with 25% of patients reporting 100% reduction in monthly migraine days. 26 Erenumab was approved by the FDA for migraine prevention in May 2018 and is currently available as monthly subcutaneous injections. Eleven RCTs investigating CGRP receptor antagonists or monoclonal antibodies are underway at the time of this writing and expected to end in 2018 or 2019. Fremanezumab and falcanezumab are FDA-approved as well.
Another major breakthrough in the treatment of migraine has been the development of 5-hydroxytryptamine 1F (5-HT1F) receptor agonists, such as lasmiditan, which are similar to triptans but without their vascular side effects. Particularly, this drug class binds more specifically to the serotonin 1F receptor than do triptans, which are less specific and bind to other vasoconstricting subtypes of serotonin receptors. 27 Effective so far in phase III trials, this drug class may be valuable for an aging population that is no longer eligible for triptan therapy because of cardiovascular and cerebrovascular risk factors. 28 
CONCLUSION
Migraine is common in primary care settings and can be difficult to treat, but there have been a multitude of recent advancements in our understanding of its pathogenesis, leading to new and exciting potential treatments. Primary care physicians are integral in the care of patients with migraine and can expect new medications to significantly improve the management of migraine in coming years. The introduction of new pharmacological agents may be extremely useful in the management of the large number of patients who have fallen out of eligibility for the use of triptans because of the associated vascular disease.
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